This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
5 Undervalued S&P 500 Stocks to Buy for 2024
by Sweta Killa
Investors seeking to tap the bullish momentum in the S&P 500 should invest in undervalued stocks like Everest Group (EG), Comcast (CMCSA), 3M Company (MMM), Molson Coors (TAP) and DaVita (DVA).
5 Top Growth Stocks to Make the Most of Santa Claus Rally
by Nalak Das
We have narrowed our search to five growth stocks that have solid upside left for the rest of 2023. These are: DOCU, DUOL, DVA, VRT, PLTR.
Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Masimo's (MASI) ORi Favored by Study for PaO2 Information
by Zacks Equity Research
Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Best Growth Stocks to Buy for December 12th
by Zacks Equity Research
GFF, DVA and EG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 12, 2023.
The Zacks Analyst Blog Highlights Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita
by Zacks Equity Research
Everest Group, Comcast, 3M, Molson Coors Beverage and DaVita are part of the Zacks top Analyst Blog.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
5 Undervalued Stocks in the S&P 500 ETF to Buy for 2024
by Sweta Killa
Many stocks in the S&P 500 ETF may be undervalued and have the potential to rise toward their peak values.
Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
McKesson (MCK) Announces Availability of FDA-Approved Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.
BD's (BDX) Novel Blood Collection System MiniDraw Gets FDA Nod
by Zacks Equity Research
BD's (BDX) FDA approval for MiniDraw will likely reshape diagnostic testing by providing a unique design that offers blood collection at any convenient location with reduced volume.
Cooper Companies (COO) Q4 Earnings In Line, '23 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) fourth-quarter fiscal 2023 revenues reflect a solid segmental performance with improved adjusted earnings amid moderating expenses.
AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
by Zacks Equity Research
AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
Centene's (CNC) Ambetter Enhances Offerings With Broward Health
by Zacks Equity Research
Centene's (CNC) Health Insurance Marketplace brand Ambetter strengthens its provider network with Broward Health.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Centene (CNC), Mindoula to Address Mental Health Issues in Indiana
by Zacks Equity Research
Centene's (CNC) unit, MHS, collaborates with Mindoula to enhance mental health support for Hoosiers and attract more customers to opt for CNC's Medicaid plans.
DaVita HealthCare (DVA) Up 22.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
OPKO Health's (OPK) potential in Rayaldee raises optimism about the stock.
Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both segments.
Top 5 Mid-Cap Stocks Likely to Turn Large-Cap in 2024
by Nalak Das
We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, XPO, AIZ, EME, DUOL.
Best Growth Stocks to Buy for December 7th
by Zacks Equity Research
EGHT, DVA and BBSI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 7, 2023.